Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy
about
Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology NursesSignaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome.Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
P2860
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting the proteasome with ...... ion and as maintenance therapy
@ast
Targeting the proteasome with ...... ion and as maintenance therapy
@en
type
label
Targeting the proteasome with ...... ion and as maintenance therapy
@ast
Targeting the proteasome with ...... ion and as maintenance therapy
@en
prefLabel
Targeting the proteasome with ...... ion and as maintenance therapy
@ast
Targeting the proteasome with ...... ion and as maintenance therapy
@en
P2860
P1476
Targeting the proteasome with ...... ion and as maintenance therapy
@en
P2093
Christina M Annunziata
Jason Burris
P2860
P304
P356
10.1097/MJT.0B013E3181FF7A9E
P577
2012-03-01T00:00:00Z